Journal of the American Academy of Child & Adolescent Psychiatry
SPECIAL SECTION: TREATMENT FOR ADOLESCENTS WITH DEPRESSION STUDY-TADSRemission and Residual Symptoms After Short-Term Treatment in the Treatment of Adolescents With Depression Study (TADS)
Section snippets
Study Participants
The study sample was composed of 439 adolescents who met DSM-IV criteria for MDD and had a CDRS-R score of ≥45 at study entry. The demographic and clinical characteristics of the TADS sample are described in a prior report (TADS, 2005). Study participants were randomized to one of the four treatment conditions: COMB (n = 107), FLX (n = 109), CBT (n = 111), and PBO (n =112).
Measures
During the acute phase of treatment, participants were assessed by a blinded independent evaluator (IE) at baseline, week
Remission Rates
The rate of remitted subjects at the end of treatment, based on the dichotomized CDRS-R, was 102 of 439, or 23%. There was a significant overall treatment (Wald X2 = 17.08, df = 3, p = .0007) and site (Wald X2 = 21.5, df = 12, p = .04) effect. More specifically, the COMB group with a 37% remission rate was superior to all of the other treatment conditions (FLX: 23%, p = .02; CBT: 16%, p = .0004; PBO: 17%, p = .0009). However, the FLX, CBT, and PBO rates were not statistically different from one
DISCUSSION
In this study of adolescents suffering from moderate to severe MDD, the combination of the antidepressant FLX and CBT was statistically and clinically superior to monotherapy with FLX, CBT, or PBO using a criterion measure of remission. Thirty-seven percent of those treated with COMB achieved remission. Treatment with either monotherapy, although effective in decreasing symptoms, was associated with low remission rates (23% for FLX and 16% for CBT) and neither was statistically different from
REFERENCES (40)
- et al.
Group cognitive-behavioral treatment for depressed adolescent offspring of depressed parents in a health maintenance organization
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Prodromal symptoms in primary major depressive disorder
J Affect Disord
(1990) - et al.
Residual symptoms in depression: an emerging therapeutic target
Prog Neuropsychopharmacol Biol Psychiatry
(2002) - et al.
Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse
J Affect Disord
(1998) - et al.
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL): initial reliability and validity data
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression
Biol Psychiatry
(1998) - et al.
Double depression: a distinctive subtype of unipolar depression
J Affect Disord
(1997)
Efficacy of paroxetine in the treatment of adolescent major depression: a randomized controlled trial
J Am Acad Child Adolesc Psychiatry
Cognitive-behavioral treatment for depressed adolescents
Behav Ther
The Treatment for Adolescents With Depression Study (TADS): methods and message at 12 weeks
J Am Acad Child Adolesc Psychiatry
A randomised controlled outpatient trial of cognitive-behavioural treatment for children and adolescents with depression: 9-month follow-up
J Affect Disord
A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy
Arch Gen Psychiatry
Partial remission in depressive disorders
Acta Psychiatr Scand
Clinical Practice Guideline. Depression in Primary Care. Volume 2. Treatment of Major Depression (AHCPR publication no. 93–0551)
A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression
Arch Gen Psychiatry
Depressive relapses and incomplete recovery from index episode
Am J Psychiatry
Cognitive behavioral treatment of residual symptoms in primary major depressive disorder
Am J Psychiatry
Cited by (215)
Sleep and Mood Disorders Among Youth
2024, Psychiatric Clinics of North AmericaClinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders
2023, Journal of the American Academy of Child and Adolescent PsychiatryEarly reduction in irritability is associated with improved outcomes among youth with depression: Findings from the AMOD study
2023, Journal of Affective DisordersOverview of treatment-resistant depression
2023, Progress in Brain Research
See end of text for author affiliations.
National Institute of Mental Health (NIMH) Program Staff participated in the design and implementation of the TADS, analysis of the data, and in authoring this article. Lilly, Inc. provided fluoxetine and matching placebo under an independent educational grant to Duke University but otherwise had no role in the design or implementation of the study, data analysis, or in authoring this manuscript. The authors are indebted to the TADS scientific advisors (Susan Essock, Ph.D., Mount Sinai School of Medicine; Barbara Geller, M.D., Washington University in St. Louis; Joel Greenhouse, Ph.D., Carnegie Mellon University; Robert Johnson, M.D., New Jersey Medical School; James Leckman, M.D., Yale University; Lydia Lewis, Depression and Bipolar Support Alliance; Sue Marcus, Ph.D., Mount Sinai School of Medicine; Kevin Stark, Ph.D., University of Texas at Austin) for their contributions to the design and methods of the study; to our cognitive-behavioral therapy consultants, David Brent, M.D., and Greg Clarke, Ph.D.; to the Columbia Suicidality Classification Group led by Kelly Posner, Ph.D., including Maria Oquendo, M.D., Madelyn Gould, Ph.D., M.P.H., and Barbara Stanley, Ph.D.; and to the members of the NIMH Data and Safety Monitoring Board for monitoring the progress of the study. The protocol and manuals used in this study can be found on the web at https://trialweb.dcri.duke.edu/tads/manuals.html. The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the NIMH, the National Institutes of Health, or the Department of Health and Human Services.
TADS is supported by contract RFP-NIH-NIMH 98-DS-0008 from NIMH to Duke University Medical Center (John March, principal investigator).
Disclosure: Dr. Silva is a consultant to Pfizer. Dr. Kratochvil is a consultant or scientific advisor to Eli Lilly, Shire, Cephalon, Organon, AstraZeneca, Boehringer-Ingelheim, Abbott, and Pfizer; he receives research support from Eli Lilly, McNeil, Cephalon, and Abbott; receives study drug for an NIMH-funded study from Lilly; and is on the Eli Lilly speakers' bureau. Dr. Weller is a consultant to and receives grants from Otsuka, Johnson & Johnson, AstraZeneca, Organon, Pharma, Shire, and GlaxoSmithKline. Dr. Ginsburg has received research support from Pfizer. Dr. Pathak receives research support from Forest Laboratories. Dr. Emslie receives research support from Eli Lilly, Organon, and Forest Laboratories; is a consultant to Eli Lilly, GlaxoSmithKline, Forest Laboratories, Wyeth-Ayerst, and Pfizer; and is on the speakers' bureau for McNeil. Dr. March is a speaker for Pfizer and Eli Lilly and has received researched support from Eli Lilly, Pfizer, and Wyeth. The other authors have no financial relationships to disclose.